WHO Technical Report Series, No. 981 - World Health Organization

WHO Expert Committee on Specifications for Pharmaceutical Preparations Forty-seventh report
WHO Technical Report Series, No. 981, 2013
56
Public Health, Nonthaburi, Thailand; Mr R. Tribe, Holder, ACT, Australia;
Associate Professor Trinh Van Lau, Director, National Institute of Drug Quality
Control, Hanoi, Viet Nam; Professor Tu Guoshi, National Institute for the Control
of Pharmaceutical and Biological Products, Ministry of Public Health, Beijing,
People’s Republic of China; Dr C. Tuleu, Senior Lecturer and Deputy Director,
Department of Pharmaceutics and Centre for Paediatric Pharmacy Research,
School of Pharmacy, University of London, London, England; Dr Richard Turner,
British Pharmacopoeia Commission, Medicines and Healthcare Products
Regulatory Agency, London, England; United States of America Food and Drug
Administration, Center for Drug Evaluation and Research, Silver Spring, MD,
USA; United States of America Food and Drug Administration, Office of Pediatric
Therapeutics, Office of the Commissioner, Rockville, MD, USA; Ms E. Uramis,
GMP Advisor, Oficina Central Polo Científico, La Havana, Cuba; Dr A.R.T.
Utami, National Agency for Drugs and Food Control, Jakarta Pusat, Indonesia;
Mrs M. Vallender, Editor-in-Chief, British Pharmacopoeia Commission
Secretariat, London, England; Mr M. van Bruggen, EU Liaison – Regulatory
Intelligence, F. Hoffmann-La Roche, Basel, Switzerland; Mr F. Vandendriessche,
Merck, Sharp and Dohme Europe, Brussels, Belgium; Dr J.E. van Oudtshoorn,
Pretoria, South Africa; Dr A.J. van Zyl, Cape Town, South Africa; Mr A. Vezali
Montai, Specialist in Regulation and GMP, Agência Nacional de Vigilância,
Brasília, Brazil; Mrs L. Vignoli, Regulatory Affairs, Pharmaceuticals and
Cosmetics, Roquette Cie, Lestren, France; Dr O. del Rosario Villalva Rojas,
Executive Director, Quality Control Laboratories, National Quality Control
Center, National Institute of Health, Lima, Peru; Mr L. Viornery, Agence nationale
de sécurité du médicament et des produits de santé, Saint Denis, France; Dr L.
Virgili, USA; Mr Wang Ju, Deputy Commissioner, Dalian Food and Drug
Administration, Dalian, Liaoning, People's Republic of China; Mr P. Wang,
Deputy Secretary-General, Chinese Pharmacopoeia Commission, Beijing,
People’s Republic of China; Dr G. Wang'ang'a, Head, Microbiological and Medical
Devices Units, National Quality Control Laboratory, Nairobi, Kenya; Dr A. Ward,
Regulatory Affairs, Avecia Vaccines, Billingham, England; Dr D. Waters, Acting
Scientific Operations Advisor, Office of Laboratories and Scientific Services,
Therapeutic Goods Administration, Woden, ACT, Australia; Dr W. Watson,
Associate Manager, CMC Regulatory Affairs, Gilead Sciences International,
Cambridge, England; Dr D.E. Webber, Director-General, World Self-Medication
Industry, Ferney-Voltaire, France; Professor W. Wieniawski, Polish Pharmaceutical
Society, Warsaw, Poland; Dr S. Wolfgang, US Food and Drug Administration,
Silver Spring, MD, USA; Mr E. Wondemagegnehu Biwota, Addis Ababa, Ethiopia;
World Self-Medication Industry, Ferney-Voltaire, France; Dr B. Wright, Group
Manager, GMP/GDP, North East Region, Medicines Inspectorate, Medicines and
Healthcare Products Regulatory Agency, York, England; Ms X. Wu, Counsellor,
Intellectual Property Division, World Trade Organization, Geneva, Switzerland;